Last reviewed · How we verify
Mabthera biosimilars
15 approved
0 filed
19 Phase 3
All key patents expired
About Mabthera
Mabthera (rituximab) — originally marketed by Roche. Class: CD20-directed Cytolytic Antibody [EPC]. Target: B-lymphocyte antigen CD20. Area: Oncology. First approved 1997-01-01.
Approved biosimilars (15)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Mabthera | Roche | marketed | 1997-01-01 | |
| RITUXIMAB | marketed | 1997-01-01 | ||
| rituximab and everolimus | National Taiwan University Hospital | marketed | ||
| RIABNI | AMGEN INC | marketed | ||
| rituximab [MabThera/Rituxan] | Hoffmann-La Roche | marketed | ||
| RiTUXimab Injection [Truxima] | Laida Cuevas Palomares | marketed | ||
| Rituximab Fludarabine Cyclophosphamide | Asociacion Espanola de Hematologia y Hemoterapia | marketed | ||
| Rituximab-pvvr | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | marketed | ||
| TRUXIMA | CELLTRION INC | marketed | ||
| Rituximab Injection | Hopital Foch | marketed | ||
| rituximab combined with corticosteroids | First Affiliated Hospital, Sun Yat-Sen University | marketed | ||
| Rituximab 375 | University Hospital, Toulouse | marketed | ||
| rituximab 1000 | University Hospital, Toulouse | marketed | ||
| Rituximab infusion | Centre Hospitalier Universitaire de Saint Etienne | marketed | ||
| Rituximab (R) | National Cancer Institute (NCI) | marketed |
Filed biosimilars under regulatory review (0)
Phase 3 biosimilars (19)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Rituximab, Methotrexate, Temozolomide | Assistance Publique - Hôpitaux de Paris | phase 3 | ||
| Rituximab - CVP | The Lymphoma Academic Research Organisation | phase 3 | ||
| Rituximab (Mabthera) | Shereen Medhat Mohammed Elsayed Nassar | phase 3 | ||
| RITUXIMAB + DHAP | GlaxoSmithKline | phase 3 | ||
| Rituximab Monotherapy | Beijing Friendship Hospital | phase 3 | ||
| Rituximab (US) | Amgen | phase 3 | ||
| Rituximab and Hyaluronidase Human | National Cancer Institute (NCI) | phase 3 | ||
| Rituximab IV | Hoffmann-La Roche | phase 3 | ||
| Rituximab plus CHOP | Sinocelltech Ltd. | phase 3 | ||
| Rituximab (Arm B) | Ostfold Hospital Trust | phase 3 | ||
| rituximab maintenance | Ludwig-Maximilians - University of Munich | phase 3 | ||
| Rituximab window | University Hospital Muenster | phase 3 | ||
| Rituximab (EU) | Amgen | phase 3 | ||
| Rituximab (Arm A) | Assistance Publique - Hôpitaux de Paris | phase 3 | ||
| rituximab+chlorambucil | International Extranodal Lymphoma Study Group (IELSG) | phase 3 | ||
| Rituximab Biosimilar | Merck Sharp & Dohme LLC | phase 3 | ||
| Rituximab sc | Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH | phase 3 | ||
| Rituximab-HDS | Gruppo Italiano Terapie Innovative nei Linfomi | phase 3 | ||
| Rituximab - CHOP | The Lymphoma Academic Research Organisation | phase 3 |
Originator patent timeline
Active patents (0)
Expired patents (0)
Subscribe to biosimilar updates
Every regulatory action on Mabthera or any of its biosimilars: